Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Clinical Applications of Pharmacogenomics in Cancer Therapy
177
34. Technology Evaluation Center. CYP2D6 pharmacogenomic of tamoxifen treatment.
Assess Prog. 2008;23(1):1–32.
35. Rohrbacher M, Kirchhof A, Geisslinger G, et al. Pyrosequencing-based screening
for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.
Pharmacogenomics. 2006;7(7):995–1002.
36. Wang H, Tompkins LM. CYP2B6: New insights into a historically overlooked cytochrome
P450 isozyme. Curr Drug Metab. 2008;9:598–610.
37. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene:
Clinical consequences. Am J Pharmacogenomics. 2001;1:189–201.
38. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: Toxicity among
marrow transplantation patients varies with the methylenetetrahydrofolate reductase
C677T polymorphism. Blood. 2001;98(1):231–4.
39. Cizmarikova M, Wagnerova M, Schonova L, et al. MDR1 (C3435T) polymorphism:
Relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J.
2010;10:62–69.
40. Keedy VL, Temin S, Somerfield MS, et al. American Society of Clinical Oncology
provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing
for patients with advanced non–small-cell lung cancer considering first-line EGFR
tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29(15):2121–27.
41. Wolff AC, Hammond EHM, Schwartz JN, et al. American Society of Clinical Oncology/
College of American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2008; 25(1):118–45.
42. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology
provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic
colorectal carcinoma to predict response to anti-epidermal growth factor receptor
monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091–96.
43. NCCN. Clinical practice guideline in oncology: Chronic myelogenic leucemia (version
1.2015). Available from: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
(accessed April 20, 2015).
44. Demetri GD, Mehren MV, Antonescu CR, et al. NCCN Task Force report: Update on
the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc
Netw. 2010;8(Suppl 2):S1–S40.
45. NCCN. Clinical practice guidelines in oncology: Acute myeloid leukemia [v.1.2015].
Available from: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf (accessed
April 2, 2015).
46. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared
with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic
results from SWOG S0124. J Clin Oncol. 2009;27:2530–35.
47. Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced
neutropenia: Dose matters. J Natl Cancer Inst. 2007;99:1290–95.
48. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the
pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic
colorectal cancer. J Clin Oncol. 2006;24:3061–68.
49. Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of
nilotinib-induced hyperbilirubinemia. Leukemia. 2007;21:2311–15.
50. Lee W, Lockhart AG, Kim RB, et al. Cancer pharmacogenomics: Powerful tools in
cancer chemotherapy and drug development. Oncologist. 2005;10:104–111.
51. Purinethol [package insert]. Horsham, PA: TEVA Biologics and Specialty Products;
2011.
52. Donnan JR, Ungar WJ, Mathews M, Hancock-Howard RL, Rahman P. A cost effectiveness
analysis of thiopurinemethyltransferase testing for guiding 6-mercaptopurine dosing
in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(2):231–9.